<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234675</url>
  </required_header>
  <id_info>
    <org_study_id>SAV-MD-17</org_study_id>
    <nct_id>NCT01234675</nct_id>
  </id_info>
  <brief_title>The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia</brief_title>
  <official_title>The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoor Ahmed M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cleveland Sleep Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia is a condition of chronic widespread pain, sleep disturbance and fatigue. Most
      of the patients with fibromyalgia complain of either non-restorative sleep or complaints of
      disturbed sleep due to pain. The proposed study is aimed at examining the effects of
      milnacipran on sleep disturbance in patients with fibromyalgia. The study is randomized,
      double-blind, placebo controlled, two way crossover PSG study to explore the effects of
      milnacipran on sleep disturbance. Patients will receive either milnacipran 50 mg BID or
      matching placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sleep disturbance in fibromyalgia is characterized as non-restorative in nature, and is
      defined as a feeling of light sleep, independent of duration, and as non-refreshing. As such,
      these patients wake up in the morning and complain of stiffness and overall aching of the
      body.

      It is well known that reciprocal relationship exist between sleep and pain, with sleep
      disturbances being an important contributor to morbidity in fibromyalgia. Milnacipran, a
      selective serotonin norepinephrine receptor inhibitor (SNRI)), was approved by the FDA for
      the management of fibromyalgia. Although milnacipran has extensively been studied in
      fibromyalgia patients, but there is no objective measure, i.e., the use of overnight
      polysomnography, to determine its effects on sleep.

      The study is meant to explore the effects of milnacipran, versus placebo, on sleep in
      patients with fibromyalgia as measured by overnight PSGs. The study will also involve
      important domains of fibromyalgia etiology: sleep disturbance, pain, fatigue and quality of
      life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overnight Polysomnography to Measure Sleep Disturbance With Milnacipran Treatment</measure>
    <time_frame>Overnight PSG week 5/ up to week 12; milnacipran treatment</time_frame>
    <description>Sleep measures at week 5 of the treatment period I; and upto week 12 for treatment period II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Awakenings After Sleep Onset</measure>
    <time_frame>Overnight PSG week 5/ upto week 12; milnacipran treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>Overnight PSG week 5/ upto week 12; milnacipran treatment</time_frame>
    <description>Percentage of Total sleep time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arousal Index</measure>
    <time_frame>Overnight PSG week 5/ upto week 12; milnacipran treatment</time_frame>
    <description>Number of arousal per hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Total Sleep Time</measure>
    <time_frame>Overnight PSG week 5/ up to week 12; milnacipran treatment</time_frame>
    <description>Sleep measures at week 5 of the treatment period I; and upto week 12 for treatment period II Percentage of Total Sleep Time that was spent in various stages of sleep</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Measures With Change in Sleep and Change in Pain Measures</measure>
    <time_frame>assessments made at week 1, week 6, week 14</time_frame>
    <description>Subjective assessments will constitute secondary endpoints and will include:
• Clinical Global Impression Improvement of Illness Scale (CGI-I) Clinical Global Impression- Severity of Illness scale (CGI-S); Medical Outcomes study Sleep Scale (MOS-SS); Fibromyalgia impact questionnaire (FIQ); Brief Pain Inventory (BPI) score-short form; Patient Global Impression of change (PGI-C); Beck Depression Inventory (BDI; Fatigue Severity Scale (FSS; Numeric Rating Scale-Sleep (NRS-S), part of subjective sleep questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Sleep Disorders</condition>
  <condition>Fibromyalgia</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>Placebo/milnacipran</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo, then milnacipran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>milnacipran/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: milnacipran then placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>Placebo twice daily then 50 mg milnacipran or matching</description>
    <arm_group_label>Placebo/milnacipran</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>50 mg twice daily; then matching placebo twice daily</description>
    <arm_group_label>milnacipran/placebo</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women at least 18 years or older.

          2. Diagnosis of fibromyalgia

          3. Clinically significant sleep disturbance, defined as difficulty in maintaining sleep
             (WASO, and AI) at least three times per week for at least one month.

          4. Understand and willing to cooperate with the study procedures.

          5. Maintain a normal sleep schedule, with daytime-awake and nighttime-sleep schedule,
             with customary bedtime between 9 PM and midnight, and rise time 5 AM and 9 AM.

          6. Patients who are able to speak, read, and understand English language, and able to
             follow the study protocol, and are able to sign the informed consent.

        Exclusion Criteria:

          1. Subject has any of the following medical conditions:

             • Liver disease; blood disorder, autoimmune disease, endocrine, cardiovascular,
             hypertension, renal, hepatic, gastrointestinal, or neurological disorder; Active
             peptic ulcer or inflammatory bowel disease.

          2. Significant sleep apnea

          3. Periodic Leg Movement or RLS

          4. Any form of severe Psychiatric illness, moderate to severe depression, including
             significant risk of suicide.

          5. Patients with uncontrolled glaucoma.

          6. Inability to discontinue the prohibited medications.

          7. Female of childbearing potential not using birthcontrol measures; or lactating.

          8. History of alcohol, narcotic, benzodiazepines, or other substance abuse within the
             past one year.

          9. Patient on prohibited Medication will include but not limited to:

               -  Anxiolytics, anti-convulsants, antipsychotics, lithium, barbiturates,
                  anti-histamines, monoamine oxidase inhibitors; or medications that affect sleep

               -  Any prescription or over the counter stimulants

               -  Medications that are contraindicated with the use of milnacipran

         10. Excessive caffeine use, defined as a consumption of more than 500 mg of caffeine or
             other xanthines, smoking &gt;1/2 a pack/day, or alcohol use &gt;14 units/week.

         11. History of allergy to milnacipran.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mansoor Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Sleep Research Cneter</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rozina Aamir, MS, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Cleveland Sleep Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noel Cyrill, MD</last_name>
    <role>Study Director</role>
    <affiliation>SouthWest Cleveland Sleep Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nosson S Goldfarb, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cleveland Sleep Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Sleep Research Center</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>July 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2015</results_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cleveland Sleep Research Center</investigator_affiliation>
    <investigator_full_name>Mansoor Ahmed M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Sleep disorders</keyword>
  <keyword>Forest Laboratories</keyword>
  <keyword>Milnacipran</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Milnacipran</title>
          <description>50 mg BiD maintenance dose</description>
        </group>
        <group group_id="P2">
          <title>Milnacipran Then Placebo</title>
          <description>50 mg BiD maintenance dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>2 treatment period, with each period 6 weeks and 7 day washout period Milnacipran in treatment period 1, Placebo in treatment period 2 Placebo treatment in Period 1, and Milnacipran in Period 2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" lower_limit="28" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Polysomnography recorded sleep parameters</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Latency to persistent sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340.7" spread="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wake after sleep onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.2" spread="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of awakenings after sleep onset</title>
          <units>awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleep Efficiency</title>
          <units>percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arousal Index</title>
          <description>Number of arousals per hour</description>
          <units>arousals per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Stage Shifts</title>
          <description>Sleep stage shifts: stage 1, stage 2, stage 3, REM sleep</description>
          <units>Stage shifts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147.4" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>REM latency</title>
          <description>Time to rapid eye movement</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.5" spread="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent of Total Sleep Time</title>
          <units>percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Stage N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.9" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage N3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overnight Polysomnography to Measure Sleep Disturbance With Milnacipran Treatment</title>
        <description>Sleep measures at week 5 of the treatment period I; and upto week 12 for treatment period II</description>
        <time_frame>Overnight PSG week 5/ up to week 12; milnacipran treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Overnight Polysomnography to Measure Sleep Disturbance With Milnacipran Treatment</title>
          <description>Sleep measures at week 5 of the treatment period I; and upto week 12 for treatment period II</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Latency to Persistent Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="6.2"/>
                    <measurement group_id="O2" value="38.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Sleep Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.7" spread="19.6"/>
                    <measurement group_id="O2" value="386.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wake after sleep onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="10.8"/>
                    <measurement group_id="O2" value="53.6" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Latency to Persistent sleep</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.683</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Sleep Time</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-24.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Wake after Sleep Onset</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>22.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Measures With Change in Sleep and Change in Pain Measures</title>
        <description>Subjective assessments will constitute secondary endpoints and will include:
• Clinical Global Impression Improvement of Illness Scale (CGI-I) Clinical Global Impression- Severity of Illness scale (CGI-S); Medical Outcomes study Sleep Scale (MOS-SS); Fibromyalgia impact questionnaire (FIQ); Brief Pain Inventory (BPI) score-short form; Patient Global Impression of change (PGI-C); Beck Depression Inventory (BDI; Fatigue Severity Scale (FSS; Numeric Rating Scale-Sleep (NRS-S), part of subjective sleep questionnaire</description>
        <time_frame>assessments made at week 1, week 6, week 14</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Awakenings After Sleep Onset</title>
        <time_frame>Overnight PSG week 5/ upto week 12; milnacipran treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Awakenings After Sleep Onset</title>
          <units>Number of Awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" spread="4.5"/>
                    <measurement group_id="O2" value="34.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.424</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Efficiency</title>
        <description>Percentage of Total sleep time</description>
        <time_frame>Overnight PSG week 5/ upto week 12; milnacipran treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency</title>
          <description>Percentage of Total sleep time</description>
          <units>Percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" spread="13.8"/>
                    <measurement group_id="O2" value="83.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arousal Index</title>
        <description>Number of arousal per hours</description>
        <time_frame>Overnight PSG week 5/ upto week 12; milnacipran treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Arousal Index</title>
          <description>Number of arousal per hours</description>
          <units>Number of Arousals per hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="2.2"/>
                    <measurement group_id="O2" value="31.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Total Sleep Time</title>
        <description>Sleep measures at week 5 of the treatment period I; and upto week 12 for treatment period II Percentage of Total Sleep Time that was spent in various stages of sleep</description>
        <time_frame>Overnight PSG week 5/ up to week 12; milnacipran treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Total Sleep Time</title>
          <description>Sleep measures at week 5 of the treatment period I; and upto week 12 for treatment period II Percentage of Total Sleep Time that was spent in various stages of sleep</description>
          <units>Percent of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stage N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="0.9"/>
                    <measurement group_id="O2" value="17.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="2.5"/>
                    <measurement group_id="O2" value="61.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage N3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.7"/>
                    <measurement group_id="O2" value="9.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="2.1"/>
                    <measurement group_id="O2" value="18.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stage N1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stage N2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.903</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stage N3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>REM</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected on and after Day 1 of the first treatment period. The data collection continued till the two weeks after the second treatment period.</time_frame>
      <desc>Additional data was collected after the end of study visit if the patient reported an adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Milnacipran</title>
          <description>Drug: milnacipran, 50 mg twice daily for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Drug: Placebo 50 mg, twice daily for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gall Stones</sub_title>
                <description>During the study the subject was diagnosed with having gall stones. After the blind was broken, the site found out that she was on placebo, and was never treated with the study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Heartrate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>nausea and vomiting</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Increased Perspirations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cold sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Petechial rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Worsening of pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive menstrual bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abnormal ejaculation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cold/flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Streptococcal infection (throat)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A well-established adaptation and re-adaptation to laboratory effects may have compromised our results. Other study biases include biases inherent in the crossover design, and a small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mansoor Ahmed, MD</name_or_title>
      <organization>Cleveland Sleep Research Center</organization>
      <phone>4402438044</phone>
      <email>sleepresearchcenter@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

